Skip to main content
VIVOZON PHARMACEUTICAL CO., LTD. logo

VIVOZON PHARMACEUTICAL CO., LTD. — Investor Relations & Filings

Ticker · 082800 ISIN · KR7082800004 KO Manufacturing
Open in API
Filings indexed 590 across all filing types
Latest filing 2022-04-05 Share Issue/Capital Cha…
Country KR South Korea
Listing KO 082800

About VIVOZON PHARMACEUTICAL CO., LTD.

https://www.vivozon.com/

VIVOZON PHARMACEUTICAL CO., LTD. is a research and development company specializing in the discovery and commercialization of innovative drugs, with a primary focus on pain and central nervous system (CNS) diseases. The company utilizes a multi-target drug development platform to create new chemical entities that act on multiple targets to achieve synergistic efficacy. This approach integrates efficacy-based screening from the early stages of discovery to identify candidate substances with a high potential for successful clinical development. Its lead pipeline candidate is Opiranserin (VVZ-149), a first-in-class, non-narcotic injectable analgesic for post-operative pain management. The company is actively expanding its pipeline to address a broader range of unmet medical needs within the CNS field.

Recent filings

Filing Released Lang Actions
증권발행결과(자율공시)(제3자배정 유상증자)
Share Issue/Capital Change Classification · 100% confidence The document is a formal announcement regarding the results of a third-party capital increase (share issuance) by Vivozon Healthcare. It details the number of shares issued, the total amount raised, and the payment date. This falls under the category of share issuance and capital changes.
2022-04-05 Korean
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official report of the results of a General Meeting of Shareholders (정기주주총회결과), detailing the approval of financial statements, dividend resolutions, and board appointments. This falls under the category of Declaration of Voting Results & Voting Rights Announcements (DVA), as it provides the official outcome of the shareholder votes held on 2022-03-30.
2022-03-30 Korean
주요사항보고서(타법인주식및출자증권양수결정)
M&A Activity Classification · 100% confidence The document is a 'Major Report' (주요사항보고서) filed with the Financial Services Commission/Korea Exchange regarding the acquisition of shares in another corporation (타법인 주식 및 출자증권 양수결정). This type of regulatory filing in the Korean market is a standard disclosure for material corporate events, which falls under the 'Regulatory Filings' category as it does not fit into specific categories like M&A (which usually refers to full company takeovers/mergers) or other specialized reports.
2022-03-25 Korean
단기차입금증가결정
Capital/Financing Update Classification · 100% confidence The document is a formal announcement regarding a decision to increase short-term borrowings (단기차입금증가결정) by the company Vivozon Healthcare. It details the loan amount, the purpose of the borrowing (funding for stock acquisition), and the board's resolution date. This falls under the category of corporate financing and capital structure updates.
2022-03-25 Korean
주요사항보고서(유상증자결정)
Capital/Financing Update Classification · 100% confidence The document is a 'Major Matters Report' (주요사항보고서) filed with the Financial Supervisory Service/Korea Exchange, specifically detailing a 'Decision on Paid-in Capital Increase' (유상증자결정). It outlines the issuance of new shares, the purpose of the capital raise (operating funds), the third-party allocation details, and the board resolution date. This falls under the category of capital structure changes and financing activities.
2022-03-25 Korean
감사보고서제출
Audit Report / Information Classification · 100% confidence The document is a formal regulatory filing titled '감사보고서 제출' (Submission of Audit Report) submitted to the Korea Exchange (KRX). It provides a summary of financial data, audit opinions, and key financial metrics (assets, liabilities, profit/loss) for the fiscal year. While it contains financial data, it is a structured disclosure announcement regarding the submission of the audit report rather than the full annual report (10-K) itself. Therefore, it is classified as an Audit Report/Information document. FY 2021
2022-03-22 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.